Ticker > Company >

Prism Medico &Pharma share price

Prism Medico and Pharmacy Ltd.

BSE: 512217 SECTOR: Trading  9.95 K   22   1

28.20
-0.14 (-0.49%)
BSE: 07 Jul 04:01 PM

Price Summary

Today's High

₹ 28.6

Today's Low

₹ 26.95

52 Week High

₹ 34.49

52 Week Low

₹ 12.49

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

38.25 Cr.

Enterprise Value

38.18 Cr.

No. of Shares

1.36 Cr.

P/E

119.54

P/B

1.67

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  16.89

CASH

0.07 Cr.

DEBT

0 Cr.

Promoter Holding

25.49 %

EPS (TTM)

₹  0.24

Sales Growth

-78.4%

ROE

-0.32 %

ROCE

-0.42%

Profit Growth

-127.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-78.4%
3 Year-57.86%
5 Year-52.77%

Profit Growth

1 Year-127.57%
3 Year23.16%
5 Year0.61%

ROE%

1 Year-0.32%
3 Year-0.34%
5 Year-0.98%

ROCE %

1 Year-0.42%
3 Year-0.43%
5 Year-1.31%

Debt/Equity

0

Price to Cash Flow

-2318.11

Interest Cover Ratio

-37.7059

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2026 25.49 0.00
Dec 2025 25.00 0.00
Sep 2025 25.00 0.00
Jun 2025 25.00 0.00
Mar 2025 25.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 32.4323.

 Limitations

  • The company has shown a poor revenue growth of -57.8589103273586% for the Past 3 years.
  • Company has a poor ROE of -0.338% over the past 3 years.
  • Company has a poor ROCE of -0.4324% over the past 3 years
  • Company has high debtor days of 2100.7572.
  • Company has negative cash flow from operations of -0.0165.
  • The company has a low EBITDA margin of -6.24216% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 87.3796.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 0.07 1.59 0.5 0.07 0.28
Total Expenditure 0.06 0.94 0.6 0.09 0.41
Operating Profit 0.01 0.65 -0.1 -0.02 -0.12
Other Income 0.01 0 0.02 0.01 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.02 0.65 -0.09 -0.01 -0.12
Tax -0.02 -0.01 0 0 0.12
Profit After Tax 0.04 0.66 -0.09 -0.01 -0.24
Adjusted EPS (Rs) 0.07 1.08 -0.14 -0.02 -0.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 16.76 8.44 1.27 2.93 0.63
Total Expenditure 16.93 8.93 1.37 3.06 0.71
Operating Profit -0.16 -0.49 -0.1 -0.14 -0.08
Other Income 0 0 0 0.12 0.02
Interest 0 0 0 0.01 0
Depreciation 0.01 0.01 0.01 0.01 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.18 -0.5 -0.1 -0.03 -0.07
Tax -0.05 -0.13 -0.03 -0.01 -0.02
Net Profit -0.13 -0.37 -0.08 -0.02 -0.05
Adjusted EPS (Rs.) -0.21 -0.61 -0.13 -0.04 -0.08

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 6.06 6.06 6.06 6.06 6.06
Total Reserves 6.86 6.49 9.1 9.08 9.03
Borrowings 0 0 0 0 0
Other N/C liabilities -0.06 -0.19 -0.21 -0.22 -0.24
Current liabilities 8.62 0.02 0.23 0.1 0.47
Total Liabilities 21.48 12.38 15.18 15.02 15.33
Assets
Net Block 0.06 0.05 0.04 0.03 0.03
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 1.94 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 19.49 12.34 15.14 14.99 15.3
Total Assets 21.48 12.38 15.18 15.02 15.33
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -0.18 -0.5 -0.1 -0.03 -0.07
Adjustment 0.01 0.01 2.96 0.01 0.01
Changes in Assets & Liabilities 0.11 -1.89 0.37 0.01 0.04
Tax Paid 0 0 -0.27 0 0
Operating Cash Flow -0.05 -2.38 2.95 -0.01 -0.02
Investing Cash Flow 0.02 2.35 -2.91 0 0
Financing Cash Flow 0 0 0 -0.01 0
Net Cash Flow -0.03 -0.03 0.04 -0.01 -0.02

Corporate Actions

Investors Details

PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
promoters 25.00 25.00 25.00 25.00 25.49
galaxy vitacare private l... 8.62 8.62 8.62 8.62 8.62
jasjot singh - - - - 0.49
ramit walia 2.39 2.39 2.39 2.39 2.39
symbiosis pharmaceutical ... 13.99 13.99 13.99 13.99 13.99
PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
investors 75.00 75.00 75.00 75.00 74.51
anil kumar 2.20 7.15 2.20 2.20 2.20
anilkumar . 4.78 - 4.95 4.95 1.65
anshul jajoo - 1.17 1.37 1.62 2.11
bosco armando menezes - - - - 2.47
emily bosco menezes - - - - 2.47
miral hemantbhai bhoot 1.39 1.39 1.39 1.39 1.39
mouna m jain - - - - 1.98
reeta devi - - - - 2.30
axter pharmaceuticals pri... - - 1.11 1.14 -
llp 0.22 0.22 0.22 0.17 -
nishikant singh - 1.13 1.13 1.19 -
prakash chand chaganlal 1.15 1.15 1.15 1.15 -
symbiosis bioscience priv... - - - 1.02 -
vinita jain 4.83 4.95 4.95 4.95 -
mukesh commercial private... - - 1.15 - -
rainbow securities privat... 1.14 1.14 1.14 - -
shresth hanuman kanodia 1.32 1.29 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Prism Medico And Pharmacy informs about closure of trading window 30 Jun, 4:34 PM Prism Medico And Pharmacy informs about publication of corrigendum notice 19 Mar, 3:31 PM Prism Medico and Pharmacy informs about annual report 6 Sep, 3:58 PM Prism Medico - Quaterly Results 14 Aug, 2:52 PM Prism Medico - Quaterly Results 14 Feb, 5:29 PM Prism Medico - Quaterly Results 14 Aug, 1:40 PM Prism Medico - Quaterly Results 13 Feb, 4:20 PM Prism Medico And Pharmacy informs about board meeting 1 Nov, 3:14 PM Prism Medico And Pharmacy informs about disclosure 19 Jun, 12:15 PM Prism Medico and Pharmacy informs about disclosure 25 May, 12:26 PM Prism Medico And Pharmacy informs about disclosure 25 May, 10:16 AM Prism Medico And Pharmacy informs about press release 20 Feb, 3:03 PM Prism Medico And Pharmacy informs about updates 17 Feb, 3:06 PM Prism Medico And Pharmacy informs about compliance certificate 15 Oct, 12:08 PM Prism Medico And Pharmacy informs about proceedings of AGM 1 Oct, 1:24 PM Prism Medico - Quaterly Results 25 May, 3:59 PM Prism Medico - Quaterly Results 25 May, 3:59 PM Prism Medico - Quaterly Results 25 May, 3:59 PM Prism Medico And Pharmacy informs about disclosure 26 Apr, 2:34 PM Prism Medico - Quaterly Results 1 Feb, 4:37 PM Prism Medico - Quaterly Results 1 Feb, 4:37 PM Prism Medico - Quaterly Results 1 Feb, 4:37 PM Prism Medico And Pharmacy informs about press release 6 Jan, 4:36 PM Prism Medico And Pharmacy informs about disclosure 27 Aug, 1:59 PM Prism Medico and Pharmacy informs about notice of 19th AGM 25 Aug, 1:47 PM Prism Medico And Pharmacy informs about outcome of board meeting 20 Aug, 3:25 PM Prism Medico and pharmacy informs about disclosure 19 Aug, 4:06 PM Prism Medico and Pharmacy informs about disclosure 24 Jul, 10:14 AM Prism Medico & Pharmacy informs about board meeting 12 Jul, 12:01 PM Prism Medico and Pharmacy informs about disclosure 4 Jun, 5:22 PM Prism Medico and Pharmacy informs about non-applicability of secretarial compliance report 2 Jun, 2:34 PM Prism Medico and Pharmacy informs about disclosure 26 May, 12:28 PM Prism Medico and Pharmacy informs about audited financial results 27 Apr, 3:15 PM Prism Medico and Pharmacy submits compliance certificate 22 Apr, 12:33 PM Prism Medico and Pharmacy informs about resignation of director 11 Nov, 4:37 PM Prism Medico And Pharmacy informs about disclosure 1 Aug, 4:34 PM Prism Medico and Pharmacy informs about website updation 22 May, 3:34 PM Prism Medico and Pharmacy informs about compliance certificate 20 May, 1:15 PM

Prism Medico &Pharma Stock Price Analysis and Quick Research Report. Is Prism Medico &Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Prism Medico &Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Prism Medico &Pharma has a PE ratio of 119.54217888936 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Prism Medico &Pharma has ROA of -0.3209% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Prism Medico &Pharma has a Current ratio of 32.4323.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Prism Medico &Pharma has a ROE of -0.3222%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Prism Medico &Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Prism Medico &Pharma has reported revenue growth of -78.3981% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Prism Medico &Pharma for the current financial year is -12.0905206520019%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Prism Medico &Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Prism Medico &Pharma is Rs 0.2359. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Prism Medico &Pharma in Ticker for free. Also, one can get the intrinsic value of Prism Medico &Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Prism Medico &Pharma FAQs

Q1. What is Prism Medico &Pharma share price today?
Ans: The current share price of Prism Medico &Pharma is Rs 28.2.

Q2. What is the market capitalisation of Prism Medico &Pharma?
Ans: Prism Medico &Pharma has a market capitalisation of Rs 38.24886696 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Prism Medico &Pharma?
Ans: The PE ratio of Prism Medico &Pharma is 119.54217888936 and the P/B ratio of Prism Medico &Pharma is 1.66941943275259, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Prism Medico &Pharma share?
Ans: The 52-week high share price of Prism Medico &Pharma is Rs 34.49, and the 52-week low share price of Prism Medico &Pharma is Rs 12.49.

Q5. Does Prism Medico &Pharma pay dividends?
Ans: Currently, Prism Medico &Pharma does not pay dividends. Dividend yield of Prism Medico &Pharma is around 0%.

Q6. What are the face value and book value of Prism Medico &Pharma shares?
Ans: The face value of Prism Medico &Pharma shares is Rs 10, while the book value per share of Prism Medico &Pharma is around Rs 16.8921. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Prism Medico &Pharma?
Ans: Prism Medico &Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Prism Medico &Pharma?
Ans: The ROE of Prism Medico &Pharma is -0.3222% and ROCE of Prism Medico &Pharma is -0.424%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Prism Medico &Pharma a good buy for the long term?
Ans: The Prism Medico &Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Prism Medico &Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Prism Medico &Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Prism Medico &Pharma’s financials?
Ans: You can review Prism Medico &Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Prism Medico &Pharma
X